1 citations
,
July 2024 in “Journal of Investigative Dermatology” TAK-279 effectively reduces psoriasis symptoms and is safe.
1 citations
,
January 2013 in “Digital Scholarship - UNLV (University of Nevada Reno)” Targeting neurosteroids may help prevent drug relapse.
32 citations
,
March 2009 in “AAPS PharmSciTech” April 2023 in “Journal of Investigative Dermatology” A new treatment for hair loss shows promise with fewer side effects.
July 2025 in “Frontiers in Pharmacology” G-1 promotes hair growth in female mice by activating specific signaling pathways.
December 2022 in “International Journal of Molecular Sciences” Afatinib, neratinib, and zanubrutinib could be effective against KRASG12C-mutant tumors.
March 2026 in “Preprints.org” Plerixafor may help treat pigmentation disorders by promoting skin repigmentation.
April 2016 in “Journal of Investigative Dermatology” Microneedle arrays deliver botulinum toxin effectively for sweat suppression, similar to injections.
May 2026 in “Journal of Medicinal Chemistry” dAR-6–1 is a promising new treatment for hair loss that works better than minoxidil.
July 2023 in “JAAD International” Two drugs, finasteride and minoxidil, are approved for hair loss treatment, but new therapies are being developed.
2 citations
,
February 2003 in “Annals of Neurology” Neuroimaging suggests that treatments targeting brain steroids could help control epilepsy, especially types linked to the menstrual cycle.
December 2020 in “Innovation in aging” Rapamycin treatment helps reduce brain inflammation and symptoms of mitochondrial disease by blocking specific pathways in mice.
3 citations
,
August 2025 in “Advanced Therapeutics” Engineered cytokines show promise for improving tissue healing and safety in regenerative medicine.
Gingerol may help treat chronic graft-versus-host disease by improving immune cell balance.
Customizing non-invasive treatments for head and neck neuralgia improves patient outcomes.
1 citations
,
March 2024 in “Signal transduction and targeted therapy” NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
January 2014 in “eScholarship (California Digital Library)” Targeting specific GABA receptors may help treat epilepsy and postpartum depression.
4 citations
,
April 2025 in “Frontiers in Immunology” Extracellular vesicles could offer precise treatments for psychiatric conditions by targeting brain networks.
Self-assembling peptide hydrogels effectively deliver drugs locally, enhancing treatment and reducing side effects.
May 2025 in “Medical Science Monitor” Concentrated growth factor shows promise for treating hair loss but needs more research.
October 2023 in “Frontiers in medicine” Targeted immunotherapy could be a promising new treatment for hair regrowth.
August 2016 in “Journal of Investigative Dermatology” Blocking the CCR5 receptor may be a new way to treat hair loss from alopecia areata.
November 2019 in “British Journal of Dermatology” FOL-005 peptide may help treat excessive hair growth safely.
June 2026 in “Frontiers in Nutrition” GLP-1 receptor agonists can help manage PCOS metabolism but need careful use before conception.
6 citations
,
September 2024 in “BMC Pulmonary Medicine” Cepharanthine may help treat lung fibrosis by affecting certain immune cells.
July 2024 in “Journal of Investigative Dermatology” A new test helps find drugs to treat head and neck cancer by targeting c-Rel.
November 2023 in “ACS Omega” New liposome treatment successfully delivers CRISPR to deactivate a key enzyme in androgen-related disorders.
119 citations
,
June 2005 in “Journal of Molecular and Cellular Cardiology” Potassium channel openers are effective in treating heart conditions, high blood pressure, pulmonary diseases, bladder issues, and hair loss, but more selective drugs are needed.
42 citations
,
March 2006 in “Drug Discovery Today: Therapeutic Strategies” The conclusion is that we need more effective hair loss treatments than the current ones, and these could include new drugs, gene and stem cell therapy, hormones, and scalp cooling, but they all need thorough safety testing.
June 2026 in “Open Access Research Journal of Biology and Pharmacy” Bedaquiline, Telmisartan, Diosmin, Azelastine, and Adapalene may be effective treatments for onchocerciasis.